S. Roberts

878 total citations
19 papers, 286 citations indexed

About

S. Roberts is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, S. Roberts has authored 19 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 9 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in S. Roberts's work include Hepatitis C virus research (15 papers), Liver Disease Diagnosis and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). S. Roberts is often cited by papers focused on Hepatitis C virus research (15 papers), Liver Disease Diagnosis and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). S. Roberts collaborates with scholars based in Australia, United States and United Kingdom. S. Roberts's co-authors include Stephen Pianko, F. J. Dudley, Son Nguyen, Christopher Desmond, Joanne Mitchell, M. Diago, Stefan Zeuzem, Edward Gane, Catherine Stedman and Stanislas Pol and has published in prestigious journals such as Hepatology, Journal of Hepatology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

S. Roberts

19 papers receiving 276 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Roberts Australia	10	276	250	69	24	13	19	286
Linda Baher United States	3	277 1.0×	248 1.0×	81 1.2×	32 1.3×	21 1.6×	3	288
Evguenia Svarovskaia United States	7	328 1.2×	294 1.2×	139 2.0×	12 0.5×	21 1.6×	14	339
M.J. Jimenez-Exposito Spain	7	258 0.9×	275 1.1×	91 1.3×	18 0.8×	7 0.5×	13	318
Lynn M. Frazier United States	6	277 1.0×	262 1.0×	61 0.9×	19 0.8×	10 0.8×	14	299
Krishna Chodavarapu United States	8	335 1.2×	292 1.2×	103 1.5×	20 0.8×	27 2.1×	10	346
H. Fontaine France	7	275 1.0×	265 1.1×	35 0.5×	17 0.7×	7 0.5×	22	286
Leonie Grellier United Kingdom	5	145 0.5×	132 0.5×	45 0.7×	24 1.0×	22 1.7×	6	189
Zayani Sims United States	7	373 1.4×	332 1.3×	69 1.0×	47 2.0×	24 1.8×	10	401
E Ibrányi Hungary	5	366 1.3×	339 1.4×	40 0.6×	41 1.7×	14 1.1×	13	386
E.J. Lawitz United States	12	393 1.4×	371 1.5×	93 1.3×	37 1.5×	15 1.2×	27	409

Countries citing papers authored by S. Roberts

Since Specialization

Citations

This map shows the geographic impact of S. Roberts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Roberts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Roberts more than expected).

Fields of papers citing papers by S. Roberts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Roberts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Roberts. The network helps show where S. Roberts may publish in the future.

Co-authorship network of co-authors of S. Roberts

This figure shows the co-authorship network connecting the top 25 collaborators of S. Roberts. A scholar is included among the top collaborators of S. Roberts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Roberts. S. Roberts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Wyles, David, A. Thompson, Eric Lawitz, et al.. (2017). No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies. Journal of Hepatology. 66(1). S303–S303. 5 indexed citations

Foster, Graham R., Edward Gane, Armen Asatryan, et al.. (2017). ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis. Journal of Hepatology. 66(1). S33–S33. 29 indexed citations

Cheung, Wa, et al.. (2017). Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct‐acting antivirals. Journal of Gastroenterology and Hepatology. 32(12). 1912–1912. 1 indexed citations

Hézode, Christophe, Nancy Reau, Evguenia S. Svarovskaia, et al.. (2016). Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies. Journal of Hepatology. 64(2). S399–S400. 14 indexed citations

Hassanein, Tarek, S. Roberts, Stephen D. Shafran, et al.. (2015). P0908 : Adherence to ombitasvir/paritaprevir/r, dasabuvir, and ribavirin is >98% in the Sapphire-I and Sapphire-II trials. Journal of Hepatology. 62. S685–S685. 1 indexed citations

Doehle, Brian, Evguenia S. Svarovskaia, Krishna Chodavarapu, et al.. (2015). P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks. Journal of Hepatology. 62. S678–S678. 4 indexed citations

Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2013). 1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY. Journal of Hepatology. 58. S498–S498. 1 indexed citations

Asselah, Tarik, S Zeuzem, Vincent Soriano, et al.. (2013). 1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2. Journal of Hepatology. 58. S482–S482. 3 indexed citations

Andreoné, Pietro, Thomas Berg, Stanislas Pol, et al.. (2012). T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study. Digestive and Liver Disease. 44. S24–S24. 16 indexed citations

10.

Kitson, Matthew T., G.J. Dore, Peter Button, et al.. (2012). 1126 VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT. Journal of Hepatology. 56. S443–S444. 1 indexed citations

11.

Soriano, Vincent, Edward Gane, P. Angus, et al.. (2012). 1420 THE EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF BI201335 AND BI207127 IN GENOTYPE 1 HCV PATIENTS WITH CIRRHOSIS - INTERIM ANALYSIS FROM SOUND-C2. Journal of Hepatology. 56. S559–S559. 15 indexed citations

12.

Zeuzem, Stefan, Pietro Andreoné, Stanislas Pol, et al.. (2011). 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 54. S3–S3. 23 indexed citations

13.

Roberts, S., John E. Ray, William Sievert, et al.. (2011). 401 EARLY ON-TREATMENT PLASMA RIBAVIRIN CONCENTRATIONS ARE ASSOCIATED WITH ON-TREATMENT ANAEMIA AND TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS. Journal of Hepatology. 54. S161–S161. 1 indexed citations

14.

Gane, Edward, S. Roberts, Catherine Stedman, et al.. (2011). 1323 THE EFFECT OF HOST IL28B GENOTYPE ON EARLY VIRAL KINETICS DURING INTERFERON-FREE TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC). Journal of Hepatology. 54. S521–S522. 10 indexed citations

15.

Sievert, William, G.J. Dore, Geoffrey W. McCaughan, et al.. (2009). SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY. Hepatology. 50(4). 1 indexed citations

16.

Gane, Edward, S. Roberts, Catherine Stedman, et al.. (2009). 1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1. Journal of Hepatology. 50. S380–S380. 42 indexed citations

17.

Zeuzem, Stefan, A. Albertí, William Rosenberg, et al.. (2006). Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity. Alimentary Pharmacology & Therapeutics. 24(8). 1133–1149. 32 indexed citations

18.

Roberts, S., Graham Cooksley, David Shaw, et al.. (2006). 731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients. Journal of Hepatology. 44. S269–S269. 36 indexed citations

19.

Desmond, Christopher, S. Roberts, F. J. Dudley, et al.. (2005). Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting. Journal of Viral Hepatitis. 13(5). 311–315. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact